Skip to main content
Fig. 1 | Molecular Neurodegeneration

Fig. 1

From: Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease

Fig. 1

Effect of test compounds on oxidative stress induced pathological tritium release after rotenone treatment (a, c); on electrical field stimulation (EFS) evoked [3H]DA release (b) and on the tritium composition in the effluent (d, e) in rat striatal slices. a, b. Oxidative stress was mimicked by the perfusion of H2O2 (250 μM), as indicated by the horizontal bar on a. Control slices were perfused identically with Krebs’ solution, but without H2O2. Test compounds or their vehicle (CTRL) were administered 18 min before the perfusion with H2O2 and onwards. b. SZV558 or its vehicle (CTRL) was administered 18 min before EFS2 and onwards. The release of [3H]DA and its tritiated metabolites is expressed as fractional release (%). N = 4-8 independent experiment/group. c When the effects of drugs were compared on H2O2 evoked tritium release, the net release evoked by H2O2 calculated by the area-under-the-curve method was taken into account. N = 4-8 independent experiment/group. Symbols represent significant changes from control slices (+++ P < 0.001), and H2O2 treated slices (*P < 0.05, **P < 0.01, ***P < 0.001), respectively. Statistical analysis: one-way ANOVA followed by the Tukey test. d, e The samples labelled by arrows (R1, S1) on a were analyzed by HPLC to identify the composition of the tritium label. The composition of the tritium efflux is expressed as percentage of the total tritium efflux. N = 6-8

Back to article page